Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma

BACKGROUND: We conducted a phase I trial of cisplatin-pemetrexed-imatinib mesylate, an oral PDGFR inhibitor, in chemo-naive MPM patients. METHODS: A standard 3+3 dose-escalating trial was used with the endpoints of MTD, response rate, survival, safety/toxicity and tumor PDGFR levels. RESULTS: 17 MPM...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Lung Cancer
Main Authors: Tsao, AS, Harun, N, Lee, J.J, Heymach, J, Pisters, K, Hong, WK, Fujimoto, J, Wistuba, I
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5080907/
https://ncbi.nlm.nih.gov/pubmed/24492162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.12.008
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares